Oxford BioDynamics (OBD) Competitors

11.7% of Oxford BioDynamics shares are held by institutional investors. Comparatively, 3.5% of SkinBioTherapeutics shares are held by institutional investors. 52.8% of Oxford BioDynamics shares are held by insiders. Comparatively, 2.7% of SkinBioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

SkinBioTherapeutics has higher revenue and earnings than Oxford BioDynamics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Oxford BioDynamics had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for SkinBioTherapeutics. Oxford BioDynamics' average media sentiment score of 0.35 beat SkinBioTherapeutics' score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the media.

SkinBioTherapeutics has a net margin of -8.73% compared to Oxford BioDynamics' net margin of -825.61%. SkinBioTherapeutics' return on equity of -5.25% beat Oxford BioDynamics' return on equity.

Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, SkinBioTherapeutics has a beta of 0.104, suggesting that its share price is 90% less volatile than the broader market.

In the previous week, Oxford BioDynamics had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for Fusion Antibodies. Oxford BioDynamics' average media sentiment score of 0.35 beat Fusion Antibodies' score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the news media.

Fusion Antibodies has a beta of 1.244, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market.

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by company insiders. Comparatively, 52.8% of Oxford BioDynamics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Fusion Antibodies has a net margin of -54.45% compared to Oxford BioDynamics' net margin of -825.61%. Fusion Antibodies' return on equity of -97.87% beat Oxford BioDynamics' return on equity.

Fusion Antibodies has higher revenue and earnings than Oxford BioDynamics. Fusion Antibodies is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

NetScientific has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

In the previous week, Oxford BioDynamics had 1 more articles in the media than NetScientific. MarketBeat recorded 1 mentions for Oxford BioDynamics and 0 mentions for NetScientific. Oxford BioDynamics' average media sentiment score of 0.35 beat NetScientific's score of 0.00 indicating that Oxford BioDynamics is being referred to more favorably in the news media.

14.7% of NetScientific shares are held by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are held by institutional investors. 42.4% of NetScientific shares are held by insiders. Comparatively, 52.8% of Oxford BioDynamics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NetScientific has a net margin of -182.91% compared to Oxford BioDynamics' net margin of -825.61%. NetScientific's return on equity of -13.70% beat Oxford BioDynamics' return on equity.

NetScientific has higher revenue and earnings than Oxford BioDynamics. Oxford BioDynamics is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

Aptamer Group has a beta of 0.871, meaning that its share price is 13% less volatile than the broader market. Comparatively, Oxford BioDynamics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Aptamer Group has higher revenue and earnings than Oxford BioDynamics. Aptamer Group is trading at a lower price-to-earnings ratio than Oxford BioDynamics, indicating that it is currently the more affordable of the two stocks.

3.4% of Aptamer Group shares are owned by institutional investors. Comparatively, 11.7% of Oxford BioDynamics shares are owned by institutional investors. 7.6% of Aptamer Group shares are owned by insiders. Comparatively, 52.8% of Oxford BioDynamics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aptamer Group and Aptamer Group both had 1 articles in the media. Oxford BioDynamics' average media sentiment score of 0.35 beat Aptamer Group's score of -0.63 indicating that Oxford BioDynamics is being referred to more favorably in the news media.

Aptamer Group has a net margin of -178.52% compared to Oxford BioDynamics' net margin of -825.61%. Aptamer Group's return on equity of -135.35% beat Oxford BioDynamics' return on equity.